Drs. Mahtani, McArthur, & O’Dea Break Down DESTINY-Breast09, PATINA, & HER2CLIMB-05

Recent updates in HER2-positive metastatic breast cancer highlight evolving first-line strategies and maintenance approaches. The DESTINY-Breast09 trial demonst...
Read More
Drs. Mahtani, McArthur, & O’Dea Break Down DESTINY-Breast09, PATINA, & HER2CLIMB-05

Latest Videos

T-DXd Moves Earlier in HER2+ Breast Cancer: DESTINY-Breast05 & DB-11

T-DXd Moves Earlier in HER2+ Breast Cancer: DESTINY-Breast05 & DB-11

Recent results presented at SABCS 2025 highlight the expanding role of trastuzumab deruxtecan (T-DXd) in HER2-positive early breast cancer. Findings from DESTIN...
Watch Now
SABCS 2025: Platinum and Neoadjuvant Strategies in Early TNBC

SABCS 2025: Platinum and Neoadjuvant Strategies in Early TNBC

New data presented at SABCS 2025 reinforced the role of platinum-based therapy in early-stage triple-negative breast cancer, showing improved pathologic complet...
Watch Now
Drs. Mahtani, McArthur, & O’Dea Discuss First-Line ADCs in PD-L1–Negative TNBC

Drs. Mahtani, McArthur, & O’Dea Discuss First-Line ADCs in PD-L1–Negative TNBC

Drs. Reshma Mahtani, Heather McArthur, and Anne O’Dea discuss new first-line treatment options for PD-L1–negative metastatic triple-negative breast cancer prese...
Watch Now
Drs. Mahtani, McArthur, & O’Dea Discuss NCCN Guideline Updates & SABCS 2025 TNBC Data

Drs. Mahtani, McArthur, & O’Dea Discuss NCCN Guideline Updates & SABCS 2025 TNBC Data

Recent updates from SABCS 2025 highlight significant progress in the treatment of metastatic triple-negative breast cancer (TNBC), particularly with the growing...
Watch Now